The effect of selective serotonin reuptake inhibitors on cognitive function in patients with Alzheimer’s disease and vascular dementia: focusing on fluoxetine with long follow-up periods
Open accessAbstract
Alzheimer’s disease (AD) and vascular dementia (VaD) are two of the most common forms of dementia, resulting in increased disability and mortality, impaired quality of life, and serious burdens on society and caregivers. However, the presently available drugs can only alleviate symptoms for a short time without delaying the progression of the cognitive disorders. Since 2003, no new drugs have been approved by the US Food and Drug Administration for the treatment of AD. In 2019, phase III clinical trials of crenezumab and aducanumab, two anti-amyloid beta monoclonal antibodies, were terminated. The scant progress in clinical trials urges efforts towards an alternative therapeutic strategy for dementia.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Considering the inherent challenges in designing drugs for previously deemed undruggable proteins, due to the presence of flat surfaces and the lack of active sites, coupled with the direct correlation between protein levels and disease, direct regulation of disease-related proteins has emerged as an exceptionally promising therapeutic strategy.
“Considering the inherent challenges in designing drugs for previously deemed undruggable proteins, due to the presence of flat surfaces and the lack of active sites, coupled with the direct correlation between protein levels and disease, direct regulation of disease-related proteins has emerged as an exceptionally promising therapeutic strategy.475”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [475]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
History and progress of hypotheses and clinical trials for Alzheimer’s disease
Liu, P.-P., Xie, Y., Meng, X.-Y., & Kang, J.-S. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0063-8 · Cited by 723 · see citing works
Self-citationDoes Fluoxetine Have Any Effect on the Cognition of Patients With Mild Cognitive Impairment?
Mowla, A., Mosavinasab, M., & Pani, A. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31802e0002 · Cited by 141 · see citing works
Mowla, A., Mosavinasab, M., Haghshenas, H., & Borhani‐Haghighi, A. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31814b98c1 · Cited by 115 · see citing works
Kessing, L. V., Søndergård, L., Forman, J. L., & Andersen, P. K. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.11.020 · Cited by 113 · cited 1× · see citing works
“Another study found increased rates of dementia during the initial prescription periods and then reductions in the rate of dementia during continued long-term antidepressant treatment.(9) However, our meta-analysis demonstrates that fluoxetine treatment for 8–12 weeks is associated with improved MMSE performance (Fig.”
BackgroundWang, Y., Tai, P.-A., Poly, T. N., Islam, M. M., Yang, H., Wu, C.-C., & Li, Y. (2018) · Behavioural Neurology · doi:10.1155/2018/5315098 · Cited by 111 · see citing works
Sepehry, A. A., Lee, P. E., Hsiung, G. Y. R., Beattie, B. L., & Jacova, C. (2012) · Drugs & Aging · doi:10.1007/s40266-012-0012-5 · Cited by 94 · see citing works
Zhang, J., Liu, X., Sun, D., Fan, Y., Zhou, H., & Fu, B. (2014) · Clinical Interventions in Aging · doi:10.2147/cia.s58830 · Cited by 49 · see citing works
Jones, H. E., Joshi, A., Shenkin, S. D., & Mead, G. E. (2016) · Age and Ageing · doi:10.1093/ageing/afw053 · Cited by 36 · see citing works
THE CURATIVE EFFECTS OF FLUOXETINE ON VASCULAR DEMENTIA
Li, X. (2005) · Journal of Linyi Medical College · Cited by 1 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
History and progress of hypotheses and clinical trials for Alzheimer’s disease
Liu, P.-P., Xie, Y., Meng, X.-Y., & Kang, J.-S. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0063-8 · Cited by 723 · see citing works
Self-citationRecent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396 · see citing works
Alzheimer’s Disease: Exploring the Landscape of Cognitive Decline
Tenchov, R., Sasso, J. M., & Zhou, Q. A. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00339 · Cited by 170 · see citing works
- Authors
- Xie, Y., Liu, P.-P., Lian, Y.-J., Liu, H.-B., & Kang, J.-S.
- Affiliations
- First Affiliated Hospital of Zhengzhou University (CN)
- Corresponding author
- Kang, Jian-Sheng
- Venue
- Signal Transduction and Targeted Therapy
- Published
- 2019-08-30
- Volume
- 4
- Issue
- 1
- Pages
- 30-30
- ISSN
- 2059-3635 (ISSN-L)
- PMC
- PMC6799811
- OpenAlex
- W2971223791
- Cited by
- 49
- References
- 9
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 5 · 2023: 8 · 2022: 10 · 2021: 10 · 2020: 6 · 2019: 1
- FWCI
- 5.38
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Signal Transduction and Targeted Therapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- National Natural Science Foundation of China (973 Program, 31171369)
- Chinese Academy of Sciences
- Zhengzhou University
- First Affiliated Hospital of Zhengzhou University
- National Key Research and Development Program of China (2010CB912001)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology › Cholinesterase and Neurodegenerative Diseases
- Keywords
- selective serotonin reuptake inhibitors, fluoxetine, Alzheimer's disease, vascular dementia, cognitive function, dementia treatment, long-term follow-up, anti-amyloid beta monoclonal antibody, crenezumab, aducanumab
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
